These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37661259)

  • 1. Evaluation of the safety and immunological effects of Bacillus Calmette-Guérin in combination with checkpoint inhibitor therapy in a patient with neuroendocrine carcinoma: a case report.
    Föhse K; Debisarun PA; Kilic G; van Dodewaard-de Jong JM; Netea MG
    J Med Case Rep; 2023 Sep; 17(1):377. PubMed ID: 37661259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Preclinical Therapies for Bladder Cancer Following Bacillus Calmette-Guérin Failure.
    Nazmifar M; Williams C; Naser-Tavakolian A; Heard J; Rosser C; Theodorescu D; Ahdoot M
    J Urol; 2023 Jan; 209(1):32-48. PubMed ID: 36067380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment.
    Alanee S; Sana S; El-Zawahry A; Peabody J; Pearce T; Adams N; Deebajah M; Crabtree J; Delfino K; McVary K; Robinson K; Rao K
    World J Urol; 2021 Oct; 39(10):3807-3813. PubMed ID: 33966128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin.
    Meghani K; Cooley LF; Choy B; Kocherginsky M; Swaminathan S; Munir SS; Svatek RS; Kuzel T; Meeks JJ
    Eur Urol; 2022 Dec; 82(6):602-610. PubMed ID: 36008193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCG vaccination induces innate immune memory in γδ T cells in humans.
    Suen TK; Moorlag SJCFM; Li W; de Bree LCJ; Koeken VACM; Mourits VP; Dijkstra H; Lemmers H; Bhat J; Xu CJ; Joosten LAB; Schultze JL; Li Y; Placek K; Netea MG
    J Leukoc Biol; 2024 Jan; 115(1):149-163. PubMed ID: 37672677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cuproptosis-associated 11 gene signature as a predictor for outcomes and response to Bacillus Calmette-Guerin and immune checkpoint inhibitor therapies in bladder carcinoma.
    Yuan H; Xiu Y; Liu T; Fan Y; Xu D
    Front Immunol; 2023; 14():1126247. PubMed ID: 37207200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
    Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
    J Urol; 2018 Jun; 199(6):1446-1451. PubMed ID: 29307686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
    Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
    J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
    Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
    Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
    Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
    J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review.
    García-Perdomo HA; Sánchez AL; Spiess PE
    Urol Oncol; 2022 Sep; 40(9):409.e1-409.e8. PubMed ID: 35232680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
    Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
    Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
    Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
    Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
    J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.
    Herr HW; Badalament RA; Amato DA; Laudone VP; Fair WR; Whitmore WF
    J Urol; 1989 Jan; 141(1):22-9. PubMed ID: 2908949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.
    Meng MV; Gschwend JE; Shore N; Grossfeld GD; Mostafid H; Black PC
    J Urol; 2019 Dec; 202(6):1111-1119. PubMed ID: 31042108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.
    Colombel M; Saint F; Chopin D; Malavaud B; Nicolas L; Rischmann P
    J Urol; 2006 Sep; 176(3):935-9. PubMed ID: 16890660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study.
    Pfister C; Kerkeni W; Rigaud J; Le Gal S; Saint F; Colombel M; Guy L; Wallerand H; Irani J; Soulie M;
    Int J Urol; 2015 Jan; 22(1):53-60. PubMed ID: 25256813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMGB1 release by urothelial carcinoma cells in response to Bacillus Calmette-Guérin functions as a paracrine factor to potentiate the direct cellular effects of Bacillus Calmette-Guérin.
    Zhang G; Chen F; Cao Y; Amos JV; Shah G; See WA
    J Urol; 2013 Sep; 190(3):1076-82. PubMed ID: 23353043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.